{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Almeida DV"],"funding":["HHS | National Institutes of Health"],"pagination":["e00259-20"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7269501"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["64(6)"],"pubmed_abstract":["Telacebec (Q203) is a new antitubercular drug with extremely potent activity against Mycobacterium ulcerans Here, we explored the treatment-shortening potential of Q203 alone or in combination with rifampin (RIF) in a mouse footpad infection model. The first study compared Q203 at 5 and 10 mg/kg doses alone and with rifampin. Q203 alone rendered most mouse footpads culture negative in 2 weeks. Combining Q203 with rifampin resulted in a relapse-free cure 24 weeks after completing 2 weeks of treatment, compared to a 25% relapse rate in mice receiving RIF with clarithromycin, the current standard of care, for 4 weeks. The second study explored the dose-ranging activity of Q203 alone and with RIF, including the extended activity of Q203 after treatment discontinuation. The bactericidal activit"],"journal":["Antimicrobial agents and chemotherapy"],"pubmed_title":["Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model."],"pmcid":["PMC7269501"],"funding_grant_id":["R01-AI113266"],"pubmed_authors":["Converse PJ","Nuermberger EL","Omansen TF","Almeida DV","Kim J","Tyagi S","Tasneen R"],"additional_accession":[]},"is_claimable":false,"name":"Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model.","description":"Telacebec (Q203) is a new antitubercular drug with extremely potent activity against Mycobacterium ulcerans Here, we explored the treatment-shortening potential of Q203 alone or in combination with rifampin (RIF) in a mouse footpad infection model. The first study compared Q203 at 5 and 10 mg/kg doses alone and with rifampin. Q203 alone rendered most mouse footpads culture negative in 2 weeks. Combining Q203 with rifampin resulted in a relapse-free cure 24 weeks after completing 2 weeks of treatment, compared to a 25% relapse rate in mice receiving RIF with clarithromycin, the current standard of care, for 4 weeks. The second study explored the dose-ranging activity of Q203 alone and with RIF, including the extended activity of Q203 after treatment discontinuation. The bactericidal activit","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2025-04-05T14:00:08.473Z","creation":"2025-04-05T14:00:08.473Z"},"accession":"S-EPMC7269501","cross_references":{"pubmed":["32205344"],"doi":["10.1128/AAC.00259-20","10.1128/aac.00259-20"]}}